Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) received final approval from the U.S. Food and Drug Administration to manufacture and market Perampanel Tablets in strengths ranging from 2 mg to 12 mg, according to an Oct. 3 exchange filing.
The product will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary, and launched in the third quarter of fiscal 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.